Wednesday 30 January 2019
The new treatment is in the Accelerated Evolution Biotechnologies, under the direction of Dr. Chief Executive Officer Dr. Ilan Morad.
"We believe we will offer a full cancer treatment a year," said Dan Aridor, Chairman of the Board of Directors. "Our cancer treatment will be effective from the first day, it will last for several weeks and will have minimal or no side effects at much lower costs than most other treatments on the market."
The treatment, called "MuTaTo," will use a combination of anticancer peptides and a toxin that specifically kills cancer cells.
Treatment will eventually be individualized and patients receive a specific cocktail of drugs by type of cancer, Morad told reporters.
Despite the importance of the announcement, some voices question the functioning of the new treatment, for example, considering that it was tested only in mice.
In this regard, the deputy director of the National Cancer Institute's office, Len Lichtenfeld, said on the agency's blog that "it is obvious that we all share the hope they are good."
"Unfortunately, we must know that this is far from effective treatment for people with cancer, much less medication," he said.
Finally, the expert noted that Israeli scientists publicly did not show the data collected to support his announcement, in addition to not disclosing evidence that the treatment was successful in the mouse, and made it clear that so far everything that has been done is an interview with local media, as published by publimetro.cl.
Information about the Chronicle.